Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
In a study of 12 adults with primary immunodeficiency and gastrointestinal distress, in-depth interviews were used to explore their experiences and the actions they take to relieve GI…
The phase 3 Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig (CARES10) study was designed to evaluate the safety, efficacy, and pharmacokinetics of a 10% intravenous immunoglobulin in…
In a study designed to investigate the biological relevance of PARP1 in multiple myeloma (MM), data revealed a significant correlation between increased PARP1 mRNA expression and poor prognosis…
In a study designed to analyze and improve the diagnostic sensitivity and specificity of the immunodeficiency disease-related scoring system in adult patients referred to immunology with clinical suspicion…
Corey Cutler, MD, MPH, medical director of the Adult Stem Cell Transplantation Center at Dana-Farber Cancer Institute, discusses Blood and Marrow Clinical Trials Network Study 1102, comparing patients…
Phase 3 ASCERTAIN Trial Shows Promising Results with Oral Decitabine and Cedazuridine Combination for the Treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Naval Daver, MD, University of Texas MD Anderson Cancer Center, shares recent work on combination magrolimab, a CD47-targeting monoclonal antibody, and the hypomethylating agent azacitidine. The azacitidine and…
Sergio Rutella, MD, PhD, FRCPath, hematologist and professor of cancer immunotherapy at the John van Geest Cancer Research Centre, reports new findings from his work on acute myeloid…
Thomas Prebet, MD, PhD, Yale School of Medicine, previews recent advancements and treatment options for acute myeloid leukemia (AML) patients with TP53, IDH, and FLT3 mutations. Dr. Prebet…
Roger H. Kobayashi, MD, clinical professor at UCLA School of Medicine, discusses primary immunodeficiency in geriatric patients at the Immune Deficiency Foundation’s National Summit. Primary immunodeficiency is not…
